THE TAPE
REPL · Biotechnology · $2.0B

Replimune Group, Inc.

$21.41▼ −2.19%
Last close
Relative strength
99RS
of 99, against every stock• 0 on the month
Powering up
Developing
+248.0%
six months against Biotechnology
52-week range
−9.0%
from the high
$1.50$23.54
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
No US GAAP filings to read.
Why it is on no screen

REPL is off the screens on one check: a base has formed.

A base has formedNo pause of 3 weeks or more inside the last 24 weeks.
Long enough to countNeeds a base first.
Shallow enoughNeeds a base first.
Close to its pivotNeeds a base first.
Relative strengthRS 99 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance

No price has been tested three times in the last 120 sessions: it has not spent long enough in one range to form a level.

The read

Replimune Group, Inc. is not on any of the screens right now. Its relative strength rating is 99, and it sits in Biotechnology.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+91.6%
Three months against its industry
+46.5%
Six months against its industry
+248.0%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 7.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-12
-6.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
+8.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Tightening after a sharp runTape · 2026-11-07
range halved after a +89% thrust, at 21.62
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
GappedTape · 2026-11-04
+6.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week highTape · 2026-11-03
3.2x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-11-03
+10.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-03
4.0 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
New 52-week highTape · 2026-10-30
2.3x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
8
$1,671,104 total

Sold: SLATTERY JOSEPH P, Dhingra Kapil, Hill Emily Luisa, Patel Sushil, Xynos Konstantinos, Schwendenman Andrew, Sarchi Christopher.

Not counted above: 2 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-09 SLATTERY JOSEPH P · Directorsell5,200$113,360
2026-11-02 Dhingra Kapil · Directoroption exercise43,169$75,546
2026-11-02 Dhingra Kapil · Directorsell21,500$408,500
2026-08-20 Astley-Sparke Philip · Directorgift50,000
2026-08-17 Hill Emily Luisa · Chief Financial Officersell9,256$132,176
2026-08-10 Patel Sushil · Chief Executive Officer, Directorsell39,341$510,253
2026-08-10 Hill Emily Luisa · Chief Financial Officersell11,448$148,481
2026-08-10 Xynos Konstantinos · Chief Medical Officersell11,447$148,468

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy5
Hold0
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Replimune Group, Inc. (REPL) — The Tape